EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Survival outcomes and prognostic factors in bladder cancer treated with radiotherapy

Koyo Kikuchi, Ibuki Ota, Takafumi Segawa, Yoshiro Ieko, Hirobumi Oikawa, Ryuji Nakamura, Hisanori Ariga

Journal of Radiation Research · 2025

DOI: 10.1093/jrr/rraf018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Radiation Research, 2025. Verfasst von Koyo Kikuchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Iwate Medical University School of Medicine, 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated survival outcomes and prognostic factors in patients with bladder cancer treated with radiotherapy. A retrospective analysis was conducted on 488 patients across all cancer stages who received radiotherapy at two institutions between 1 January 2000 and 31 December 2022. Overall survival (OS) was assessed based on treatment intent (radical or palliative) and cancer stage. Among these patients, 304 with Stage II–III disease who underwent radical radiotherapy were further analyzed for OS and prognostic factors using Kaplan–Meier methods and Cox regression analysis. In the radical radiotherapy group, median survival times (MSTs) were 43 months for Stage 0–I, 29 months for Stage II–III, and 17 months for Stage IV (M0). In the palliative radiotherapy group, MSTs were 16 months (95% confidence interval [CI]: 11–25) for M0 and 9 months (95% CI: 7–15) for M1. Among the 304 patients with Stage II–III disease treated with radical radiotherapy, the 3-year OS rate was 43.0%. Hydronephrosis was the only independent prognostic factor significantly associated with worse OS (hazard ratio: 1.915, P < 0.001). Age, sex, stage, treatment era, prophylactic pelvic radiotherapy, chemotherapy and prescribed dose had no significant impact on OS. Radiotherapy remains a viable treatment option for patients at any stage of cancer. Although hydronephrosis negatively affects survival, it should not preclude the use of radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsHumansMaleFemalePrognosisAgedMiddle AgedTreatment OutcomeAged, 80 and overKaplan-Meier EstimateAdultNeoplasm StagingProportional Hazards ModelsRetrospective Studies

Stichwörter der Autor:innen

prognosisradiotherapysurvival rateurinary bladder neoplasms

Autor:innen und Institutionen

  • Department of Radiation Oncology, Iwate Medical University School of Medicine, 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695, Japan.
  • Department of Radiation Oncology, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Morioka, Iwate 020-0066, Japan.
  • Department of Radiology, Morioka Red Cross Hospital, 6-1-1 Sanbonyanagi, Morioka, Iwate 020-8560, Japan.

Zitieren

APA

Kikuchi, K., Ota, I., Segawa, T., Ieko, Y., Oikawa, H., Nakamura, R., & Ariga, H. (2025). Survival outcomes and prognostic factors in bladder cancer treated with radiotherapy. Journal of Radiation Research. https://doi.org/10.1093/jrr/rraf018

Vancouver

Kikuchi K, Ota I, Segawa T, Ieko Y, Oikawa H, Nakamura R, et al. Survival outcomes and prognostic factors in bladder cancer treated with radiotherapy. Journal of Radiation Research. 2025. doi:10.1093/jrr/rraf018

BibTeX
@article{Kikuchi2025,
  author = {Kikuchi, Koyo and Ota, Ibuki and Segawa, Takafumi and Ieko, Yoshiro and Oikawa, Hirobumi and Nakamura, Ryuji and Ariga, Hisanori},
  title = {Survival outcomes and prognostic factors in bladder cancer treated with radiotherapy},
  journal = {Journal of Radiation Research},
  year = {2025},
  doi = {10.1093/jrr/rraf018}
}
Kostenlos starten →